The first Tuesday of May every year is World Asthma Day. At a recent 2025 World Asthma Day event, medical experts gave lectures and health consultations on asthma prevention and treatment knowledge. Experts say that currently, the proportion of asthma patients receiving standardized treatment does not exceed 70%, and in some areas, it is only 40% -50%. Although some asthma patients can completely improve after several years of standardized treatment and reach the condition of stopping medication, theoretically asthma patients need to take medication for life, and stopping medication without authorization can easily cause lung function damage. Xu Jinfu, Vice President of East China Hospital affiliated with Fudan University, said, "When evaluating whether asthma patients are well controlled, we do not simply judge based on the patient's own feelings, but on whether they have (symptoms) completely controlled for a relatively long period of time. At the same time, we also need to cooperate with some examinations and tests to comprehensively evaluate." For severe asthma patients who cannot improve their asthma condition after conventional inhalation therapy or oral corticosteroids, experts say that the application of biological targeted drugs can help patients achieve standardized control of their condition as much as possible. Song Yuanlin, Director of the Department of Respiratory and Critical Care Medicine at Zhongshan Hospital affiliated with Fudan University, stated that biological targeted therapy has been a very good treatment option in the field of asthma in recent years. By inhibiting the release of some inflammatory factors in the respiratory tract, eosinophils are reduced. By targeting its core pathogenic mechanisms and key targets, treatment can achieve very good results. The "Guidelines for the Prevention and Treatment of Bronchial Asthma (2024 Edition)" states that for some patients in the clinical control period, if there are no acute asthma attacks or other symptoms within one year after biological targeted drug therapy or other anti asthma treatments, and lung function is basically normal, and oral corticosteroids are not needed, it can be called a clinical cure. Zhang Min, Director of the Department of Respiratory and Critical Care Medicine at the First People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, told reporters, "Recently, there has been a very leapfrog development in the treatment of asthma, which is actually a breakthrough in many of our biological targeted therapies. It will be more precise. The control of inflammation in asthma, especially in acute attacks, can be reduced by 70% to 80%. With our current diagnostic and treatment methods and management capabilities, some patients can completely achieve clinical cure